Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Regulation of Lipolysis and Adipose Tissue Signaling during Acute Endotoxin-Induced Inflammation: A Human Randomized Crossover Trial

  • Nikolaj Rittig ,

    Affiliation Department of Internal Medicne and Endocrinology (MEA) and Medical Research Laboratory, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus, C, Denmark

  • Ermina Bach,

    Affiliation Department of Internal Medicne and Endocrinology (MEA) and Medical Research Laboratory, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus, C, Denmark

  • Henrik Holm Thomsen,

    Affiliation Department of Internal Medicne and Endocrinology (MEA) and Medical Research Laboratory, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus, C, Denmark

  • Steen Bønlykke Pedersen,

    Affiliation Department of Internal Medicne and Endocrinology (MEA) and Medical Research Laboratory, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus, C, Denmark

  • Thomas Sava Nielsen,

    Affiliation The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3b, 6.6.30, DK-2200 N, Copenhagen, Denmark

  • Jens O. Jørgensen,

    Affiliation Department of Internal Medicne and Endocrinology (MEA) and Medical Research Laboratory, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus, C, Denmark

  • Niels Jessen,

    Affiliations Department of Internal Medicne and Endocrinology (MEA) and Medical Research Laboratory, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus, C, Denmark, Research Laboratory for Biochemical Pathology, Institute for Clinical Medicine, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus, C, Denmark

  • Niels Møller

    Affiliation Department of Internal Medicne and Endocrinology (MEA) and Medical Research Laboratory, Aarhus University Hospital, Nørrebrogade 44, 8000, Aarhus, C, Denmark

Regulation of Lipolysis and Adipose Tissue Signaling during Acute Endotoxin-Induced Inflammation: A Human Randomized Crossover Trial

  • Nikolaj Rittig, 
  • Ermina Bach, 
  • Henrik Holm Thomsen, 
  • Steen Bønlykke Pedersen, 
  • Thomas Sava Nielsen, 
  • Jens O. Jørgensen, 
  • Niels Jessen, 
  • Niels Møller



Lipolysis is accelerated during the acute phase of inflammation, a process being regulated by pro-inflammatory cytokines (e.g. TNF-α), stress-hormones, and insulin. The intracellular mechanisms remain elusive and we therefore measured pro- and anti-lipolytic signaling pathways in adipocytes after in vivo endotoxin exposure.


Eight healthy, lean, male subjects were investigated using a randomized cross over trial with two interventions: i) bolus injection of saline (Placebo) and ii) bolus injection of lipopolysaccharide endotoxin (LPS). A 3H-palmitate tracer was used to measure palmitate rate of appearance (Rapalmitate) and indirect calorimetry was performed to measure energy expenditures and lipid oxidation rates. A subcutaneous abdominal fat biopsy was obtained during both interventions and subjected to western blotting and qPCR quantifications.


LPS caused a mean increase in serum free fatty acids (FFA) concentrations of 90% (CI-95%: 37–142, p = 0.005), a median increase in Rapalmitate of 117% (CI-95%: 77–166, p<0.001), a mean increase in lipid oxidation of 49% (CI-95%: 1–96, p = 0.047), and a median increase in energy expenditure of 28% (CI-95%: 16–42, p = 0.001) compared with Placebo. These effects were associated with increased phosphorylation of hormone sensitive lipase (pHSL) at ser650 in adipose tissue (p = 0.03), a trend towards elevated pHSL at ser552 (p = 0.09) and cAMP-dependent protein kinase A (PKA) phosphorylation of perilipin 1 (PLIN1) (p = 0.09). Phosphatase and tensin homolog (PTEN) also tended to increase (p = 0.08) while phosphorylation of Akt at Thr308 tended to decrease (p = 0.09) during LPS compared with Placebo. There was no difference between protein or mRNA expression of ATGL, G0S2, and CGI-58.


LPS stimulated lipolysis in adipose tissue and is associated with increased pHSL and signs of increased PLIN1 phosphorylation combined with a trend toward decreased insulin signaling. The combination of these mechanisms appear to be the driving forces behind the increased lipolysis observed in the early stages of acute inflammation and sepsis.

Trial Registration NCT01705782


Administration of bacterial endotoxin is widely used as a model of acute inflammation and sepsis [1,2]. Energy demands increase during the initial phase of sepsis and is mainly provided by lipid mobilization and oxidation [3,4]. Storage of lipids in adipose tissue constitutes the largest endogenous energy supply and lipolysis therefore becomes essential during conditions with acute increased energy demands [5]. Notably, lipolysis is elevated in septic patients during the first days of hospital admission [68]. Despite this, knowledge about the regulation of lipolysis in human adipose tissue during sepsis and acute inflammation is sparse [9].

Lipolysis is rapidly and distinctly stimulated by epinephrine, but other hormones such as cortisol and growth hormone (GH) also all contribute and increase acutely in response to sepsis [10]. In addition, bacterial products (such as endotoxins) cause increased concentrations of proinflammatory cytokines (e.g. TNF-α), which are known to have lipolytic actions [1113]. In contrary, insulin remains the principal anti-lipolytic agent, although ketone bodies also suppress lipolysis [14,15].

As reviewed in detail by others [16,17], lipolysis is tightly regulated through adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL), of which ATGL is the initial rate-limiting enzyme in the conversion of triacylglycerol (TAG) into glycerol and free fatty acids (FFA). HSL activity is regulated through phosphorylation on multiple sites by cAMP-dependent protein kinase A, also known as protein kinase A (PKA)[17]. Likewise, PKA regulates ATGL activity although by an indirect mechanism; ATGL activity is regulated through interaction with the co-regulators comparative gene-identification 58 (CGI-58) and G0/G1 switch gene protein 2 (G0S2)[17]. Thus, activation is dependent on complex formation with CGI-58 but in the basal state CGI-58 is sequestered in a complex with PLIN1. When PKA is activated it phosphorylates PLIN1, leading to the release of CGI-58 and subsequent activation of ATGL. Conversely, G0S2 is a negative regulator of ATGL activity, and the inhibitory effect of this protein is overriding activation by CGI-58 [18]. Being regulated primarily at the protein expression level GOS2 is thought to act as a key regulator of overall ATGL capacity, rather than a component of acute lipolytic cascade [17]. It is unknown if these regulatory mechanisms are affected during the acute phase of inflammation and sepsis.

The present study was designed to define, which intracellular mechanisms become activated in adipose tissue concurrent with the increased rate of lipolysis observed in the initial stages of acute inflammation, using bacterial endotoxin in a human model to replicate these metabolic events under controlled conditions.



Data originate from a randomized controlled study from which data regarding protein metabolism have been published [19]. The study design included 3 experimental settings: (i) Saline control (Placebo), (ii) LPS administration (LPS) and (iii) LPS and amino acid administration (LPS+A). Only data from study arm (i) and (ii) during non-insulin stimulated conditions are reported here. Eight healthy, young, and lean male subjects were included in this study. They were eligible for inclusion if they were of male gender, were healthy without regular intake of medication, were between 25 and 40 years of age, and had a body mass index (BMI) between 20 to 30 kg•m-2. All subjects were screened using a medical interview and a physical examination including electrocardiography and a blood test screen. An informed written and oral consent was obtained for each subject. Both study days were performed under the same conditions in the same laboratory at Aarhus University Hospital, Denmark. Subjects were without febrile illness the preceding week of each study day and did not exercise 48 hours before each visit. Subjects arrived by car at 07:00 AM after an overnight fast.


The Danish Ethical Committee approved the study (1-10-71-410-12) and both written and oral consent was obtained before inclusion of subjects in the trial. The study was conducted in accordance with the principles stated in the Declaration of Helsinki.


A minimum of 21 days separated the trials for each subject. The primary investigator enrolled all test subjects using a computerized program to randomize interventions. All subjects were blinded in regards to interventions, but could distinguish interventions due to the subjective symptoms following LPS administration. Four of the test subjects received LPS during their first trial followed by Placebo during the second trial and the other four test subjects received Placebo first followed by LPS (Fig 1). During each trial intravenous catheters were inserted in both cubital veins and one in a dorsal hand vein for intravenous infusions and blood sampling.

Lipopolysaccharide (LPS)

A bolus (1 ng/kg or 10 U/kg) of E. coli endotoxin (10,000 USP Endotoxin, lot H0K354; The United States Pharmacopeial Convention, Inc., Rockville, Maryland) was given during a two minute period at time = 0 min and followed by a 10 ml saline infusion.

Palmitate tracer and serum concentration of FFA

A continuous infusion of 3H-palmitate (infusion rate 0.3 μCi/min) was given at time = 180–240 min (Fig 2). Whole body palmitate calculations were based on Steele’s non-steady state equation [20]: Where Rapalmitate is the rate of appearance for palmitate, ipalmitate is the infusion rate of palmitate tracer, SA is the specific activity of 3H-palmitate, Vd is the total distribution volume, c is the total concentration of palmitate, ΔSA is the difference in specific activity of 3H-palmitate between samples, and Δt is the time between these samples. Vd was estimated assuming that the plasma volume constitutes 5% of total body weight and multiplied with 1.8 as shown by others [21]. Blood samples were collected before starting the 3H-palmitate infusion and again at time = 220, 230, and 240 min.

Fig 2. Flowchart showing the time course for the trial days.

At time = 0 min a bolus of isotonic saline (Placebo) or a bolus lipopolysaccharide (LPS) was given.

The mean serum concentration of FFA were quantified using blood collected at time = 220, 230, and 240 min using the in vitro enzymatic colorimetric method assay NEFA-HR(2) in accordance with manufactures guidelines (Wako Chemicals GmbH, Germany).

Indirect calorimetry

An Oxycon Pro calorimeter (Intramedic) with a canopy was applied at time = 180 min (Fig 2). A 15-minute period collection of respiratory gases was used to estimate resting energy expenditure (EE) and the respiratory quotient (RQ). Fat oxidation rates were calculated as previously described [22]. Due to technical problems, calorimetry measurements were only completed in 7 subjects.

Tissue biopsy and western blot analysis

An abdominal subcutaneous adipose tissue biopsy was obtained at time = 135 min. The biopsy was immediately washed with isotonic saline to avoid contamination of blood and snap-frozen in liquid nitrogen before storage at -80°C. Fat biopsies were successfully obtained and blotted for n = 7.

All samples were homogenized in a buffer with a 7.4 pH-level and containing 50 mM HEPES, 137 mM NaCl, 10 mM Na4P2O7, 20 mM NaF, 5 mM EDTA, 1 mM MgCl2, 1 mM CaCl2, 2 mM NaOV, 5 mM NAM, 10 μM TSA, 1% HALT, 1% NP-40, and 10% glycerol. Samples were centrifuged at 14,000 g for 20 minutes.

Western blot analyses were used to measure relative contents and phosphorylation of relevant protein targets using the BioRad Criterion system (BioRad). Primary antibodies used were ATGL (GTX62840, GeneTex), CGI-58 (ab183739, Abcam), phosphorylated HSL Ser552, Ser554, and Ser650 (4139, 4137, and 4126 Cell signaling), HSL (4107 Cell signaling), Phospho-PKA Substrate (9624 Cell signaling), PLIN1 (PA1-1052 ABR), G0S2 (sc-133424 Santa cruz), phosphorylated Akt at Thr308 and Ser473 (9275 and 9271 Cell signaling), Akt (4691, Cell signaling), phosphorylated AS160 at Thr642 (4288, Cell signaling), AS160 (07–741, Upstate), and PTEN (9188, Cell signaling). The same membrane was exposed to both Phospho-PKA Substrate antibody and PLIN1 antibody to identify the band representing PKA-phosphorylation of PLIN1. This method has been validated by others using a PLIN1 knock-out model [23].

Control for equal loading was performed using the stain-free technology [24]. Proteins were visualized and quantified using Image Lab 5.0, Bio-Rad laboratories. Data are presented as dot plots showing each subject’s quantification as a ratio compared to the median value for the Placebo group.

RNA extraction and qPCR for mRNA analysis

RNA was extracted using TRIzol (Gibco BRL, Life Technologies, Roskilde, Denmark) and homogenized with one tungsten bead (Qiagen) using a Mixer Mill. A NanoDrop 8000 Spectrophotometer (Thermo Scientific Pierce, Waltham, Maine, USA) was used to quantify RNA by measuring absorbance at 260 and 280 nm with a ratio ≥1.9. Integrity of the RNA was checked by visual inspection of the two ribosomal RNAs on an agarose gel. A Verso cDNA kit (cat# Ab-1453, Thermo Fischer Scientific) with random hexamer primers was used to synthesize the cDNA. Duplicate PCR-reactions were performed using a KAPA SYBR® FAST qPCR Kit (Kapa Biosystems, Inc. Woburn, MA, USA) in a LightCycler 480 (Roche Applied Science) using the following protocol: One step at 95°C for 3 min., then 95°C for 10 sec., 60°C for 20 sec. and 72°C for 10 sec and finally a melting curve analysis was performed. The increase in fluorescence was measured in real time during the extension step. The relative gene expression was estimated using the default “Advanced Relative Quantification” mode of the software version LCS 480 (Roche Applied Science) and specificity of the amplification was checked by a melting temperature analysis.

The following primer pairs were designed using QuantPrime [25]: ATGL: ACCTCAATGAACTTGGCACC and CAACGCCACGCACATCTA length = 122bp, G0S2: CGAGAG-CCCAGAGCC GAGATG and AGCACCACGCCGAAGAG length = 137bp, CGI58: TGTCAGCCG-GCTTCGAGATAAG and ACCAGTTAGCCATCCTGACCTCTC length = 113 bp.

The housekeeping gene, beta2microglobulin, was amplified using this primer pair: b2MG: GAGGCT-ATCCAGCGTACTCC and AATGTCGGATGGATGAAACCC, length = 111bp. Expression level of this housekeeping gene was similar between the Placebo and LPS. All primers were from DNA Technology (Risskov, Denmark). A similar set-up was used for negative controls, except that the reverse transcriptase was omitted and no PCR products were detected under these conditions. Adipose tissue for PCR analysis was only performed in 6 subjects due to lack of adipose tissue.


Data are presented as means or medians with a 95% confidential interval (CI-95%) or range when appropriate. All statistical analyses and graphs were made using Stata 13 (College Station, Texas, USA) and SigmaPlot 11 (San Jose, California, USA). A paired two-tailed students t-test was used to compare the two study arms. Normal distribution was ensured by examination of QQ-plots. Data were logarithmic converted if QQ-plots indicated unequal distribution. If data still were not normally distributed a Wilcoxon signed-ranked test was used. P-values < 0.05 were considered significant.



The test subjects had a median age of 26 years (range: 25–32), a median BMI of 23 kg•m-2 (range: 22–26), and a median body weight of 79 kg (range 68–85 kg) as reported previously [19]. LPS administration caused a significant increase in heart rate, temperature, and serum concentrations of tumor necrotic factor (TNF)-α, interleukin (IL)-6, IL-10, cortisol, GH, glucagon, FFA, and lactate compared with Placebo as reported previously [19]. Furthermore, serum insulin concentrations 15 min prior to fat biopsy sampling were 14.9 pmol/l during LPS and 31.0 pmol/l during Placebo (p<0.05).

Lipolysis and lipid oxidation

Absolute serum concentrations of FFA have been reported previously [19] and showed that LPS administration caused a mean increase of 90% (CI-95%: 37–142, p = 0.005) compared with placebo. Rapalmitate showed a median increase of 117% (CI-95%: 77–166, p<0.001) during LPS compared with Placebo (Fig 3). In addition, LPS caused a mean increase in the lipid oxidation rate of 49% (CI-95%: 1–96, p = 0.047) and a median increase in energy expenditure of 28% (CI-95%: 16–42, p = 0.001) compared with Placebo.

Fig 3. Metabolic measures.

Data are shown as dot-plots for each subject during the control conditions with saline administration (Placebo) and the day with lipopolysaccharide administration (LPS). A black horizontal bar indicates the median value for each group. A. Rapalmitate (n = 8), B. lipid oxidation rates from indirect calorimetry measurements (n = 7), and C. energy expenditure from indirect calorimtry measurements (n = 7). Paired sample t-tests were used to compare groups. Rapalmitate = rate of appearance of palmitate, FFA = free fatty acids.

Adipose tissue signaling

Western blot quantification of subcutaneous abdominal fat tissue showed an increase in HSL phosphorylation at Ser650 (p = 0.032) during LPS compared with Placebo (Fig 4). In parallel to this finding, HSL phosphorylation at Ser552 (p = 0.09) and PKA phosphorylation of PLIN1 (p = 0.09) also tended to increase during LPS compared with Placebo. We did not detect changes between groups in regards to protein levels of ATGL, CGI-58, and G0S2 as well as HSL phosphorylation at Ser554 (p>0.05). In agreement with these findings, quantitative PCR analysis showed no difference of ATGL, G0S2, and CGI-58 expression between groups (Fig 5, p>0.05).

Fig 4. Western blot analyses of subcutaneous abdominal fat tissue biopsies.

Representative western blots in abdominal adipose tissue during control conditions (Placebo) and during lipopolysaccharide (LPS) induced endotoxemia (n = 7). Data are presented as the ratio change compared to the median value for the Placebo condition. The black horizontal bars indicate the median value for each group (= 1 for Placebo in all graphs). Paired sample t-test was used to compare groups. A. G0S2 = G0/G1 switch protein 2, B. ATGL = adipose triglyceride lipase, C. CGI-58 = comparative gene identification-58, D.,E., and F. HSL = hormone sensitive lipase, and G. p-PKA Substrate = Phospho-PKA (protein kinase A) Substrate.

Fig 5. qPCR measurements of subcutaneous abdominal fat biopsies.

Quantitative PCR measurements (n = 6) of mRNA are shown for control conditions (Placebo) and during lipopolysaccharide (LPS): A. G0S2 = G0/G1 switch protein 2, B. ATGL = adipose triglyceride lipase, and C. CGI-58 = comparative gene identification-58.

Phosphatase and tensin homolog (PTEN) tended to increase (p = 0.08) and phosphorylation of Akt at Thr308 tended to decrease (p = 0.09) during LPS compared with Placebo. Phosphorylation of Akt (protein kinase B) at Ser473 together with phosphorylation of AS160 at Thr642 did not differ between groups (Fig 6).

Fig 6. Western blot analyses of subcutaneous abdominal fat tissue biopsies.

Representative western blots in abdominal adipose tissue during control conditions (Placebo) and during lipopolysaccharide (LPS) induced endotoxemia (n = 7). Data are presented as the ratio change compared to the median value for the Placebo condition. The black horizontal bars indicate the median value for each group (= 1 for Placebo in all graphs). Paired sample t-test was used to compare groups. A. PTEN = phosphatase and tensin homolog, B. and C. Akt, and D. AS160 = Akt substrate of 160 kDa.

Protein expression of PLIN1, HSL, panAkt, AS160, and β-actin did not differ significantly between groups (p>0.05, data not shown).


In this study, we demonstrate how endotoxin administration causes acute and marked increments in the circulating levels and turnover of FFA concentrations together with increased lipid oxidation and energy expenditure. These changes were associated with increased phosphorylation of HSL at Ser650. Additionally, we also detected trends towards increased phosphorylation of HSL at Ser552 and increased PKA phosphorylation of PLIN1. These findings may suggest that increased PKA activity is the driving mechanism behind the increased lipolysis seen in the early stages of acute inflammation and sepsis but are still speculative and needs to be confirmed by other human clinical randomized trials.

Our findings are in accordance with earlier studies showing increased lipolysis in the early phase of sepsis and endotoxemia [68]. Even though endotoxemia is known to cause increased lipolysis, the mechanisms responsible for this response are poorly understood. Despite the complex interaction between the numerous pro-lipolytic hormones and cytokines, they all eventually stimulate PKA-mediated phosphorylation of PLIN1 and HSL [10,17]. A study by Anthonsen et al [26] documented rat HSL phosphorylation at Ser563 and Ser660 (Ser552 and Ser650 in human HSL) in cells stimulated with isoproterenol and later it was shown that phosphorylation of PLIN1 by PKA is a decisive step in the activation of lipolysis [27].

A bolus administration of LPS is known to cause an acute increase in epinephrine, GH, and cortisol [28,29], as also observed in our study [19]; all of these hormones are pro-lipolytic. In addition, a study in humans employing direct infusion of LPS into the femoral artery has shown that LPS per se increases lipolysis, as judged by increased net palmitate release from the infused leg [11]. Insulin is known to be the main inhibitor of lipolysis [27], and serum insulin concentrations were elevated nearly two-fold during Placebo compared with LPS in our study [19] thereby also favoring increased lipolysis during LPS. These hormonal signals may be further amplified by the borderline increase of PTEN (a known inhibitor of insulin signaling) in our western blot results and the borderline decrease of phosphorylation of Akt (a known downstream effector in the insulin signaling cascade) at Thr308 during LPS compared with Placebo. This could indicate that both increased pro- and decreased anti-lipolytic agents may contribute to the increased lipolysis during the acute phase of inflammation. This is primarily a speculative consideration as results per definition were not significantly different between groups (p>0.05), which may be due to the lack of statistical power often limiting human endotoxin trials.

We used both quantitative PCR and western blot to measure G0S2, ATGL, and CGI-58 without finding any differences between LPS and Placebo. Considering the short time-interval between LPS administration and fat biopsy sampling (time = 135 min), it seems plausible and predictable that we only found differences in posttranslational protein modifications (e.g. phosphorylations) and no differences or trends when quantifying protein levels. We have previously shown that ATGL and G0S2 expression are regulated during prolonged fasting (72 h) but not affected by an acute exercise bout [30]. Moreover, in cultured adipocytes G0S2 expression is decreased substantially by exposure to TNF-α for 8 hours [18]. These observations further support the hypothesis that remodeling of the lipolytic cascade at the level of protein expression requires persistent, long-term stimulation of lipolysis. It remains intriguing, why lipolysis is increased during the first 24 h of sepsis but then decreases to lower than normal rates after four days of admission [6]. Future studies investigating this issue are necessary to fully understand how lipid mobilization is regulated during the time-course of an infection.

Our borderline significant results (0.05<p-value<0.10) in all likelihood are due to low statistical power. The number of participants in studies using LPS administration is limited by ethical considerations. In addition, the fat biopsies time-points were performed relatively early (fig 1, time = 135) because we aimed at identifying the initial adipocyte signaling modifications responsible for increasing the rate of lipolysis; and it has been shown by others that the inflammatory effects of LPS peaks 60–120 minutes following exposure [31]. It is evidently possible that we would have observed a more profound intracellular adipocyte signaling response and changes in protein expression levels if the biopsies had been performed later.

We used lean healthy men as test subjects, which may imply that our results cannot necessarily be extrapolated to other experimental or clinical situations. Furthermore, these findings were made using subcutaneous abdominal fat biopsies and we therefore do not know if our findings also apply to regulation in other adipose tissue depots. Experiments in rats suggest that visceral adipose tissue is less responsive to endotoxemia than subcutaneous adipose tissue [32] while human studies have found that visceral adipose tissue is more responsive to epinephrine and less responsive to insulin than subcutaneous adipose tissue [33,34].

In conclusion, we found that LPS administration causes an acute increase in lipolysis, FFA concentrations, energy expenditure, and lipid oxidation rates, which is associated with adipose tissue stimulation of pHSL at ser650. On a more speculative note it seems as if the initial triggering mechanisms of adipose tissue lipolysis in the acute phase of inflammation and sepsis seem to proceed through PKA-dependent activation of the classical lipolytic cascade.

Supporting Information

S1 File. Original study protocol in English.


S2 File. Original study protocol in Danish.



The authors would like to thank Annette Mengel, Lisa Buus, Elsebeth Hornemann, Eva Schriver, and Helle Zibrandtsen for their outstanding work and support during the whole study.

This work was financially supported by Aarhus University (Denmark), the Danish Council for Strategic Research (grant no. 0603-00479B), and the Lundbeck foundation (R83-A8172).

Author Contributions

  1. Conceptualization: NR EB HHT TSN JOJ NJ NM.
  2. Data curation: NR.
  3. Formal analysis: NR.
  4. Funding acquisition: NM NJ SBP.
  5. Investigation: NR HHT EB.
  6. Methodology: NR JOJ NJ NM.
  7. Project administration: NR NM.
  8. Resources: NJ SBP NM.
  9. Software: NR HHT NJ.
  10. Supervision: JOJ TSN NJ NM.
  11. Validation: HHT NJ NM.
  12. Visualization: NR TSN.
  13. Writing – original draft: NR.
  14. Writing – review & editing: NR NM.


  1. 1. Lowry SF (2005) Human endotoxemia: a model for mechanistic insight and therapeutic targeting. Shock 24 Suppl 1: 94–100. pmid:16374380
  2. 2. Calvano SE, Coyle SM (2012) Experimental human endotoxemia: a model of the systemic inflammatory response syndrome? Surg Infect (Larchmt) 13: 293–299.
  3. 3. Askanazi J, Carpentier YA, Elwyn DH, Nordenstrom J, Jeevanandam M, Rosenbaum SH, et al. (1980) Influence of total parenteral nutrition on fuel utilization in injury and sepsis. Ann Surg 191: 40–46. pmid:6766297
  4. 4. Nordenstrom J, Carpentier YA, Askanazi J, Robin AP, Elwyn DH, Hensle TW, et al. (1982) Metabolic utilization of intravenous fat emulsion during total parenteral nutrition. Ann Surg 196: 221–231. pmid:6807226
  5. 5. Cahill GF Jr. (1976) Starvation in man. Clin Endocrinol Metab 5: 397–415. pmid:182420
  6. 6. Forse RA, Leibel R, Askanazi J, Hirsch J, Kinney JM (1987) Adrenergic control of adipocyte lipolysis in trauma and sepsis. Ann Surg 206: 744–751. pmid:3689010
  7. 7. Ilias I, Vassiliadi DA, Theodorakopoulou M, Boutati E, Maratou E, Mitrou P, et al. (2014) Adipose tissue lipolysis and circulating lipids in acute and subacute critical illness: effects of shock and treatment. J Crit Care 29: 1130 e1135–1139.
  8. 8. Wellhoener P, Vietheer A, Sayk F, Schaaf B, Lehnert H, Dodt C (2011) Metabolic alterations in adipose tissue during the early phase of experimental endotoxemia in humans. Horm Metab Res 43: 754–759. pmid:22009369
  9. 9. Jha P, Claudel T, Baghdasaryan A, Mueller M, Halilbasic E, Das SK, et al. (2014) Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia. Hepatology 59: 858–869. pmid:24002947
  10. 10. Fruhbeck G, Mendez-Gimenez L, Fernandez-Formoso JA, Fernandez S, Rodriguez A (2014) Regulation of adipocyte lipolysis. Nutr Res Rev 27: 63–93. pmid:24872083
  11. 11. Buhl M, Bosnjak E, Vendelbo MH, Gjedsted J, Nielsen RR, T KH, et al. (2013) Direct effects of locally administered lipopolysaccharide on glucose, lipid, and protein metabolism in the placebo-controlled, bilaterally infused human leg. J Clin Endocrinol Metab 98: 2090–2099. pmid:23543661
  12. 12. Bach E, Moller AB, Jorgensen JO, Vendelbo MH, Jessen N, Olesen JF, et al. (2015) Intact pituitary function is decisive for the catabolic response to TNF-alpha: studies of protein, glucose and fatty acid metabolism in hypopituitary and healthy subjects. J Clin Endocrinol Metab 100: 578–586. pmid:25375979
  13. 13. Plomgaard P, Fischer CP, Ibfelt T, Pedersen BK, van Hall G (2008) Tumor necrosis factor-alpha modulates human in vivo lipolysis. J Clin Endocrinol Metab 93: 543–549. pmid:18029463
  14. 14. Moller N, Jorgensen JO, Moller J, Bak JF, Porksen N, Alberti KG, et al. (1990) Substrate metabolism during modest hyperinsulinemia in response to isolated hyperketonemia in insulin-dependent diabetic subjects. Metabolism 39: 1309–1313. pmid:2246973
  15. 15. Mikkelsen KH, Seifert T, Secher NH, Grondal T, van Hall G (2015) Systemic, cerebral and skeletal muscle ketone body and energy metabolism during acute hyper-D-beta-hydroxybutyratemia in post-absorptive healthy males. J Clin Endocrinol Metab 100: 636–643. pmid:25415176
  16. 16. Lass A, Zimmermann R, Oberer M, Zechner R (2011) Lipolysis—a highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores. Prog Lipid Res 50: 14–27. pmid:21087632
  17. 17. Nielsen TS, Jessen N, Jorgensen JO, Moller N, Lund S (2014) Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. J Mol Endocrinol 52: R199–222. pmid:24577718
  18. 18. Yang X, Lu X, Lombes M, Rha GB, Chi YI, Guerin TM, et al. (2010) The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab 11: 194–205. pmid:20197052
  19. 19. Rittig N, Bach E, Thomsen HH, Johannsen M, Jorgensen JO, Richelsen B, et al. (2015) Amino acid supplementation is anabolic during the acute phase of endotoxin-induced inflammation: A human randomized crossover trial. Clin Nutr.
  20. 20. Steele R (1959) Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82: 420–430. pmid:13833973
  21. 21. Jensen MD, Heiling V, Miles JM (1990) Measurement of non-steady-state free fatty acid turnover. Am J Physiol 258: E103–108. pmid:2405695
  22. 22. Ferrannini E (1988) The theoretical bases of indirect calorimetry: a review. Metabolism 37: 287–301. pmid:3278194
  23. 23. Miyoshi H, Souza SC, Zhang HH, Strissel KJ, Christoffolete MA, Kovsan J, et al. (2006) Perilipin promotes hormone-sensitive lipase-mediated adipocyte lipolysis via phosphorylation-dependent and -independent mechanisms. J Biol Chem 281: 15837–15844. pmid:16595669
  24. 24. Gurtler A, Kunz N, Gomolka M, Hornhardt S, Friedl AA, McDonald K, et al. (2013) Stain-Free technology as a normalization tool in Western blot analysis. Anal Biochem 433: 105–111. pmid:23085117
  25. 25. Arvidsson S, Kwasniewski M, Riano-Pachon DM, Mueller-Roeber B (2008) QuantPrime—a flexible tool for reliable high-throughput primer design for quantitative PCR. BMC Bioinformatics 9: 465. pmid:18976492
  26. 26. Anthonsen MW, Ronnstrand L, Wernstedt C, Degerman E, Holm C (1998) Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J Biol Chem 273: 215–221. pmid:9417067
  27. 27. Choi SM, Tucker DF, Gross DN, Easton RM, DiPilato LM, Dean AS, et al. (2010) Insulin regulates adipocyte lipolysis via an Akt-independent signaling pathway. Mol Cell Biol 30: 5009–5020. pmid:20733001
  28. 28. Bloesch D, Keller U, Spinas GA, Kury D, Girard J, Stauffacher W (1993) Effects of endotoxin on leucine and glucose kinetics in man: contribution of prostaglandin E2 assessed by a cyclooxygenase inhibitor. J Clin Endocrinol Metab 77: 1156–1163. pmid:8077306
  29. 29. Fong YM, Marano MA, Moldawer LL, Wei H, Calvano SE, Kenney JS, et al. (1990) The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 85: 1896–1904. pmid:2347917
  30. 30. Nielsen TS, Vendelbo MH, Jessen N, Pedersen SB, Jorgensen JO, Lund S, et al. (2011) Fasting, but not exercise, increases adipose triglyceride lipase (ATGL) protein and reduces G(0)/G(1) switch gene 2 (G0S2) protein and mRNA content in human adipose tissue. J Clin Endocrinol Metab 96: E1293–1297. pmid:21613358
  31. 31. Andreasen AS, Krabbe KS, Krogh-Madsen R, Taudorf S, Pedersen BK, Moller K (2008) Human endotoxemia as a model of systemic inflammation. Curr Med Chem 15: 1697–1705. pmid:18673219
  32. 32. Sugawara K, Miyata G, Shineha R, Satomi S (2003) The lipolytic responsiveness to endotoxin in subcutaneous adipose tissue is greater than mesenteric adipose tissue. Tohoku J Exp Med 199: 171–179. pmid:12703661
  33. 33. Lonnqvist F, Krief S, Strosberg AD, Nyberg S, Emorine LJ, Arner P (1993) Evidence for a functional beta 3-adrenoceptor in man. Br J Pharmacol 110: 929–936. pmid:7905344
  34. 34. Richelsen B, Pedersen SB, Moller-Pedersen T, Bak JF (1991) Regional differences in triglyceride breakdown in human adipose tissue: effects of catecholamines, insulin, and prostaglandin E2. Metabolism 40: 990–996. pmid:1895966